Skip to main content
Lihua Budde, MD, Oncology, Duarte, CA, City of Hope Comprehensive Cancer Center

LihuaElizabethBuddeMDPhD

Oncology Duarte, CA

Hematologic Oncology

Associate Professor, Dept. Of Hematology & HCT, City of Hope

Dr. Budde is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Budde's full profile

Already have an account?

  • Office

    Division of Lymphoma
    1500 East Duarte Road
    Duarte, CA 91010
    Phone+1 626-256-4673
    Fax+1 626-389-3058
  • Is this information wrong?

Education & Training

  • University of Washington
    University of WashingtonFellowship, Hematology and Medical Oncology, 2006 - 2009
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2003 - 2006
  • Duke University
    Duke UniversityPh.D., 1995 - 2001
  • Tongji Medical University
    Tongji Medical UniversityClass of 1995

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2012 - 2024
  • WA State Medical License
    WA State Medical License 2006 - 2013

Awards, Honors, & Recognition

  • Clinical investigator Damon runyon cancer research foundation

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis
    Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, a...
    Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia
    Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Press Mentions

  • City of Hope Clinical and Laboratory Investigators Present New Research at the 60
    City of Hope Clinical and Laboratory Investigators Present New Research at the 60December 4th, 2018
  • Mosunetuzumab plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell Lymphoma
    Mosunetuzumab plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell LymphomaDecember 23rd, 2023

Other Languages

  • Chinese (Mandarin)

Hospital Affiliations